Search results
Results from the WOW.Com Content Network
As of 5 July 2021, due to vaccine shortages, the vaccination rate has been slowed down since 20 June. The vaccination rate remains 29% for more than two weeks. [3] According to JoongAng Ilbo, as of 5 July, the remaining amount of the COVID-19 vaccine is 1.8 million doses, including 1.4 million from Pfizer. [4]
Yellow fever vaccination certificate is required if coming from endemic countries. Payment of the fee (EUR 10) by credit or debit card. Valid for one journey only and it expires once exit the country. Sierra Leone: eVisa / Visa on arrival [205] [206] 3 months / 30 days Singapore: Visa not required [207] 30 days Slovakia: Visa required [208 ...
South Korea introduced what was considered one of the largest and best-organised epidemic control programs in the world, along with Singapore, Taiwan, and Vietnam. [ 11 ] [ 12 ] [ 13 ] Various measures have been taken to mass test the population for the virus, and isolate any infected people as well as trace and quarantine those they had ...
South Korea announced on Friday that people visiting restaurants and cinemas and other public spaces will have to show vaccine passes, amid a surge in COVID-19 infections and six confirmed cases ...
ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. [2] [3] For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing. The vaccine was authorised in Japan in November 2023. [4]
The COVID-19 pandemic in Southeast Asia is part of the ongoing worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was confirmed to have spread to Southeast Asia on 13 January 2020, when a 61-year-old woman from Wuhan tested positive in Thailand , making it the ...
For premium support please call: 800-290-4726 more ways to reach us
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [2] [3] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [ 4 ]